Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.

@article{Pahler2003EffectsOT,
  title={Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.},
  author={Jessica C. Pahler and Stacey Ruiz and Irina Niemer and Leslie R Calvert and Michael Andreeff and Michael Keating and Stefan Faderl and David James McConkey},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2003},
  volume={9 12},
  pages={4570-7}
}
PURPOSE Bortezomib is a peptide boronic acid inhibitor of the proteasome developed for cancer therapy. The compound is being evaluated currently in Phase II and III clinical trials. Here we characterized the effects and mechanisms of action of bortezomib in cells obtained from patients with chronic lymphocytic leukemia (CLL). EXPERIMENTAL DESIGN We exposed isolated CLL lymphocytes from >100 patients to various concentrations of bortezomib or other proapoptotic stimuli, and measured DNA… CONTINUE READING